Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to offer a significant step forward for body management . https://getretatrutideaustralia.com/blog/retatrutide-results-side-effects-cost